Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q3877030> ?p ?o }
Showing triples 1 to 89 of
89
with 100 triples per page.
- Q3877030 subject Q7434686.
- Q3877030 subject Q8256003.
- Q3877030 subject Q8522217.
- Q3877030 subject Q8529119.
- Q3877030 subject Q9052323.
- Q3877030 abstract "Nilutamide (INN, USAN, BAN) (brand names Nilandron (US), Anandron (CA)) is a synthetic, non-steroidal, pure antiandrogen used in the treatment of advanced-stage (metastatic) prostate cancer. It was developed by Roussel, introduced in 1987, and was the second non-steroidal antiandrogen to be marketed after flutamide. Nilutamide acts as a potent and selective competitive silent antagonist of the androgen receptor (AR), which prevents testosterone and other androgens from activating the AR. Because most prostate cancer cells rely on activation of the AR for growth and survival, nilutamide can extend life in men with prostate cancer.Nilutamide is used in prostate cancer in combination with a GnRH analogue at a dosage of 300 mg daily for the first 4 weeks of treatment, and 150 mg once daily thereafter. It is not indicated as a monotherapy in prostate cancer. Nilutamide has a half-life of approximately two days, which allows for once-daily administration. In addition to prostate cancer, nilutamide has also been studied in and used as a component of hormone replacement therapy in trans women.General side effects of non-steroidal antiandrogens, including nilutamide, include gynecomastia, breast pain/tenderness, hot flashes, depression, fatigue, and sexual dysfunction. In addition, relative to other non-steroidal antiandrogens, nilutamide has been uniquely associated with mild and reversible visual disturbances (31%), a disulfiram-like alcohol intolerance (19%), and interstitial pneumonitis (1–2%) (which can progress to pulmonary fibrosis), and has a higher incidence of nausea (27%) and vomiting than other non-steroidal antiandrogens. There is also a risk of hepatoxicity with nilutamide, though occurrence is very rare and the risk is significantly less than with flutamide. The unique adverse effects of nilutamide, and especially its risk of interstitial pneumonitis, have limited its clinical use relative to other non-steroidal antiandrogens. From a safety standpoint, bicalutamide is clinically preferred over both nilutamide (due to interstitial pneumonitis) and flutamide (due to hepatotoxicity) in regards to choice of non-steroidal antiandrogen.Like other non-steroidal antiandrogens such as flutamide and bicalutamide, nilutamide, without concomitant GnRH analogue therapy, increases serum androgen (by two-fold in the case of testosterone), estrogen, and prolactin levels due to inhibition of AR-mediated suppression of steroidogenesis via negative feedback on the hypothalamic-pituitary-gonadal axis. As such, though nilutamide is still highly effective as an antiandrogen as a monotherapy, it is given in combination with a GnRH analogue such as leuprorelin in prostate cancer to suppress androgen concentrations to castrate levels in order to attain maximal androgen blockade (MAB).Like flutamide and bicalutamide, nilutamide is able to cross the blood-brain-barrier and has central antiandrogen actions.".
- Q3877030 atcPrefix "L02".
- Q3877030 atcSuffix "BB02".
- Q3877030 casNumber "63612-50-0".
- Q3877030 chEBI "7573".
- Q3877030 drugbank "DB00665".
- Q3877030 fdaUniiCode "51G6I8B902".
- Q3877030 iupacName "5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione".
- Q3877030 pubchem "4493".
- Q3877030 thumbnail Nilutamide.svg?width=300.
- Q3877030 wikiPageWikiLink Q1052281.
- Q3877030 wikiPageWikiLink Q1137463.
- Q3877030 wikiPageWikiLink Q1153419.
- Q3877030 wikiPageWikiLink Q127076.
- Q3877030 wikiPageWikiLink Q1304270.
- Q3877030 wikiPageWikiLink Q1318776.
- Q3877030 wikiPageWikiLink Q1349821.
- Q3877030 wikiPageWikiLink Q14873015.
- Q3877030 wikiPageWikiLink Q153.
- Q3877030 wikiPageWikiLink Q16.
- Q3877030 wikiPageWikiLink Q1671531.
- Q3877030 wikiPageWikiLink Q1703595.
- Q3877030 wikiPageWikiLink Q174211.
- Q3877030 wikiPageWikiLink Q177911.
- Q3877030 wikiPageWikiLink Q181257.
- Q3877030 wikiPageWikiLink Q181876.
- Q3877030 wikiPageWikiLink Q1858291.
- Q3877030 wikiPageWikiLink Q186889.
- Q3877030 wikiPageWikiLink Q1907986.
- Q3877030 wikiPageWikiLink Q1988832.
- Q3877030 wikiPageWikiLink Q1996756.
- Q3877030 wikiPageWikiLink Q2047938.
- Q3877030 wikiPageWikiLink Q20707196.
- Q3877030 wikiPageWikiLink Q20707646.
- Q3877030 wikiPageWikiLink Q21163349.
- Q3877030 wikiPageWikiLink Q221694.
- Q3877030 wikiPageWikiLink Q277954.
- Q3877030 wikiPageWikiLink Q30.
- Q3877030 wikiPageWikiLink Q321431.
- Q3877030 wikiPageWikiLink Q32446.
- Q3877030 wikiPageWikiLink Q3269441.
- Q3877030 wikiPageWikiLink Q339221.
- Q3877030 wikiPageWikiLink Q3443446.
- Q3877030 wikiPageWikiLink Q409665.
- Q3877030 wikiPageWikiLink Q410943.
- Q3877030 wikiPageWikiLink Q418669.
- Q3877030 wikiPageWikiLink Q426185.
- Q3877030 wikiPageWikiLink Q4340209.
- Q3877030 wikiPageWikiLink Q47270.
- Q3877030 wikiPageWikiLink Q47273.
- Q3877030 wikiPageWikiLink Q4926095.
- Q3877030 wikiPageWikiLink Q5156356.
- Q3877030 wikiPageWikiLink Q574820.
- Q3877030 wikiPageWikiLink Q5903807.
- Q3877030 wikiPageWikiLink Q62527.
- Q3877030 wikiPageWikiLink Q62614.
- Q3877030 wikiPageWikiLink Q7434686.
- Q3877030 wikiPageWikiLink Q7936184.
- Q3877030 wikiPageWikiLink Q824258.
- Q3877030 wikiPageWikiLink Q8256003.
- Q3877030 wikiPageWikiLink Q8522217.
- Q3877030 wikiPageWikiLink Q8529119.
- Q3877030 wikiPageWikiLink Q9052323.
- Q3877030 wikiPageWikiLink Q905999.
- Q3877030 wikiPageWikiLink Q907160.
- Q3877030 wikiPageWikiLink Q918753.
- Q3877030 wikiPageWikiLink Q9635.
- Q3877030 wikiPageWikiLink Q9690.
- Q3877030 atcPrefix "L02".
- Q3877030 atcSuffix "BB02".
- Q3877030 casNumber "63612".
- Q3877030 chebi "7573".
- Q3877030 drugbank "DB00665".
- Q3877030 iupacName "55".
- Q3877030 pubchem "4493".
- Q3877030 unii "51".
- Q3877030 type ChemicalSubstance.
- Q3877030 type Drug.
- Q3877030 type ChemicalObject.
- Q3877030 type Thing.
- Q3877030 type Q8386.
- Q3877030 comment "Nilutamide (INN, USAN, BAN) (brand names Nilandron (US), Anandron (CA)) is a synthetic, non-steroidal, pure antiandrogen used in the treatment of advanced-stage (metastatic) prostate cancer. It was developed by Roussel, introduced in 1987, and was the second non-steroidal antiandrogen to be marketed after flutamide. Nilutamide acts as a potent and selective competitive silent antagonist of the androgen receptor (AR), which prevents testosterone and other androgens from activating the AR.".
- Q3877030 label "Nilutamide".
- Q3877030 depiction Nilutamide.svg.